Pulse Biosciences, Inc Common Stock (DE) financials
$50.89−2.73%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $434.0K | $401.0K | $264.0K | $86.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $161.0K | $31.0K | $4.0K | -$193.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 37.1% | 7.7% | 1.5% | −224.4% | — | — | — | — | — | — | — | — |
| Operating income | -$25.3M | -$19.1M | -$18.3M | -$20.4M | -$20.3M | -$18.0M | -$20.3M | -$13.7M | -$11.7M | -$10.6M | -$12.5M | -$11.3M |
| Net income | -$24.7M | -$18.6M | -$17.4M | -$19.4M | -$19.2M | -$16.8M | -$19.4M | -$12.7M | -$11.4M | -$10.1M | -$11.9M | -$10.6M |
| Net margin | −5681.3% | −4633.7% | −6603.4% | −22540.7% | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.36 | $-0.27 | $-0.26 | $-0.29 | $-0.28 | $-0.25 | $-0.33 | $-0.21 | $-0.20 | $-0.18 | $-0.20 | $-0.19 |
| EBITDA | -$25.0M | -$18.9M | -$18.0M | -$20.1M | -$20.0M | -$17.8M | -$20.0M | -$13.4M | -$11.4M | -$10.3M | -$12.9M | -$11.0M |
| Operating cash flow | -$18.7M | -$14.6M | -$14.8M | -$13.0M | -$12.8M | -$13.5M | -$9.1M | -$9.0M | -$8.4M | -$9.8M | -$6.8M | -$8.7M |
| Free cash flow | -$18.8M | -$14.6M | -$14.9M | -$13.1M | -$12.9M | -$13.6M | -$9.2M | -$9.1M | -$8.4M | -$9.8M | -$6.8M | -$8.8M |
| Diluted shares | 69.2M | 68.0M | 67.8M | 67.4M | 67.3M | 67.1M | 58.2M | 61.1M | 57.2M | 57.1M | 58.6M | 56.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $101.6M | $68.3M | $80.7M | $95.2M | $106.3M | $119.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $115.6M | $81.6M | $94.5M | $108.8M | $120.3M | $133.4M |
| Total liabilities | $16.1M | $15.3M | $13.9M | $16.1M | $15.8M | $14.9M |
| Shareholders' equity | $99.5M | $66.3M | $80.7M | $92.7M | $104.5M | $118.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology